.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Risk Stratification in Metastatic Renal Cell Carcinoma

EP. 1: Risk Stratification in Metastatic Renal Cell Carcinoma

March 29th 2019

EP. 2: Favorable-Risk mRCC: Choosing Appropriate Frontline Therapy

March 29th 2019

EP. 3: Role of TKIs in Intermediate or Poor-Risk mRCC

March 29th 2019

EP. 4: mRCC: Identifying and Managing AEs in TKIs and IO Therapy

March 29th 2019

EP. 5: Evaluating I-O Monotherapy's Value in Treating mRCC

March 29th 2019

EP. 6: Frontline Therapy for mRCC: Sequencing and Goals

March 29th 2019

EP. 7: Selecting an Optimal Second-Line Regimen for mRCC

March 29th 2019

EP. 8: Goals in Previously Treated Advanced Renal Cell Carcinoma

March 29th 2019

EP. 9: Novel Combinations in mRCC: Axi/Pembro vs Axi/Avelumab

March 29th 2019

EP. 10: mRCC: When is TKI/I-O Combination Therapy Appropriate?

March 29th 2019

EP. 11: Further Exploring TKI/I-O Combination Regimens in mRCC

March 29th 2019

EP. 12: Future Directions in Renal Cell Carcinoma Management

March 29th 2019